Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2004.06.060 on January 15 2004

Journal of Clinical Oncology, Vol 22, No 4 (February 15), 2004: pp. 624-633
© 2004 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fröhling, S.
Right arrow Articles by Döhner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fröhling, S.
Right arrow Articles by Döhner, K.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations

Stefan Fröhling, Richard F. Schlenk, Ina Stolze, Jörg Bihlmayr, Axel Benner, Sylvia Kreitmeier, Karen Tobis, Hartmut Döhner, Konstanze Döhner

From the Department of Internal Medicine III, University Hospital of Ulm, Ulm; and Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany

Address reprint requests to Hartmut Döhner, MD, Department of Internal Medicine III, University Hospital of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany; e-mail: hartmut.doehner{at}medizin.uni-ulm.de

PURPOSE: To assess the prognostic relevance of mutations in the CEBPA gene encoding CCAAT/enhancer binding protein alpha (C/EBP{alpha}) in a large prospective series of younger adults with acute myeloid leukemia (AML) and normal cytogenetics.

PATIENTS AND METHODS: The entire CEBPA coding region was sequenced in diagnostic samples from 236 AML patients 16 to 60 years of age with normal cytogenetics who were uniformly treated on two consecutive protocols of the AML Study Group Ulm, and CEBPA mutation status was correlated with clinical outcome.

RESULTS: CEBPA mutations were detected in 36 (15%) of 236 patients. Twenty-one (9%) of 236 patients had mutations predicted to result in loss of C/EBP{alpha} function. Remission duration and overall survival (OS) were significantly longer for the 36 patients with CEBPA mutations (P = .01 and P = .05, respectively). On multivariate analysis, wild-type CEBPA was an independent prognostic marker affecting remission duration (hazard ratio, 2.85; P = .01) and OS (hazard ratio, 1.87; P = .04). Analysis of cooperating mutations (both types of activating FLT3 mutations and MLL partial tandem duplications) showed that FLT3 mutations had no significant prognostic influence in patients with CEBPA mutations. Furthermore, there was no significant overlap between the subgroup of patients with CEBPA mutation with predicted loss of C/EBP{alpha} function and patients with FLT3 or MLL mutations, suggesting that CEBPA loss-of-function mutations define a distinct biologic subclass of AML with normal cytogenetics.

CONCLUSION: Mutant CEBPA predicts favorable prognosis and may improve risk stratification in AML patients with normal cytogenetics.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Supported by grants P.671 and P.726 from the Medical Faculty of the University of Ulm, Germany, and by grant 01GI9981 from the Bundesministerium für Bildung und Forschung (Kompetenznetz, "Akute und chronische Leukämien"), Germany.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Loss of C/EBP{alpha} and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
    Danilo Perrotti, Guido Marcucci, and Michael A. Caligiuri
    JCO 2004 22: 582-584 [Full Text]

Related Correspondence

  • Genetic Changes of CEBPA in Cancer: Mutations or Polymorphisms?
    Carlos Resende, Gonçalo Regalo, Cecília Durães, Fátima Carneiro, and José C. Machado
    JCO 2007 25: 2493-2494 [Full Text]


This article has been cited by other articles:


Home page
 BloodHome page
P. A. Ho, T. A. Alonzo, R. B. Gerbing, J. Pollard, D. L. Stirewalt, C. Hurwitz, N. A. Heerema, B. Hirsch, S. C. Raimondi, B. Lange, et al.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Blood, June 25, 2009; 113(26): 6558 - 6566.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Schneider, E. Hoster, M. Unterhalt, S. Schneider, A. Dufour, T. Benthaus, G. Mellert, E. Zellmeier, S. K. Bohlander, M. Feuring-Buske, et al.
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)
Blood, May 21, 2009; 113(21): 5250 - 5253.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Renneville, N. Boissel, N. Gachard, D. Naguib, C. Bastard, S. de Botton, O. Nibourel, C. Pautas, O. Reman, X. Thomas, et al.
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
Blood, May 21, 2009; 113(21): 5090 - 5093.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. J. Wouters, B. Lowenberg, C. A. J. Erpelinck-Verschueren, W. L. J. van Putten, P. J. M. Valk, and R. Delwel
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Blood, March 26, 2009; 113(13): 3088 - 3091.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. E. Figueroa, B. J. Wouters, L. Skrabanek, J. Glass, Y. Li, C. A. J. Erpelinck-Verschueren, A. W. Langerak, B. Lowenberg, M. Fazzari, J. M. Greally, et al.
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features
Blood, March 19, 2009; 113(12): 2795 - 2804.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. K. Weinberg, M. Seetharam, L. Ren, K. Seo, L. Ma, J. D. Merker, J. Gotlib, J. L. Zehnder, and D. A. Arber
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
Blood, February 26, 2009; 113(9): 1906 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Koschmieder, B. Halmos, E. Levantini, and D. G. Tenen
Dysregulation of the C/EBP{alpha} Differentiation Pathway in Human Cancer
J. Clin. Oncol., February 1, 2009; 27(4): 619 - 628.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
R. F. Schlenk, K. Dohner, M. Kneba, K. Gotze, F. Hartmann, F. del Valle, H. Kirchen, E. Koller, J. T. Fischer, L. Bullinger, et al.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Haematologica, January 1, 2009; 94(1): 54 - 60.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Pabst, M. Eyholzer, S. Haefliger, J. Schardt, and B. U. Mueller
Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid Leukemia
J. Clin. Oncol., November 1, 2008; 26(31): 5088 - 5093.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, C.-G. Liu, et al.
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
J. Clin. Oncol., November 1, 2008; 26(31): 5078 - 5087.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, S. P. Whitman, K. Mrozek, K. Maharry, C. Langer, C. D. Baldus, W. Zhao, B. L. Powell, et al.
Wilms' Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol., October 1, 2008; 26(28): 4595 - 4602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Radich
Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?
J. Clin. Oncol., October 1, 2008; 26(28): 4539 - 4541.
[Full Text] [PDF]

Home page
 BloodHome page
C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C.-G. Liu, M. E. Ross, et al.
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Blood, June 1, 2008; 111(11): 5371 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Meshinchi, D. L. Stirewalt, T. A. Alonzo, T. J. Boggon, R. B. Gerbing, J. L. Rocnik, B. J. Lange, D. G. Gilliland, and J. P. Radich
Structural and numerical variation of FLT3/ITD in pediatric AML
Blood, May 15, 2008; 111(10): 4930 - 4933.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, et al.
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
N. Engl. J. Med., May 1, 2008; 358(18): 1909 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Bullinger, K. Dohner, R. Kranz, C. Stirner, S. Frohling, C. Scholl, Y. H. Kim, R. F. Schlenk, R. Tibshirani, H. Dohner, et al.
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Blood, May 1, 2008; 111(9): 4490 - 4495.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Garzon, M. Garofalo, M. P. Martelli, R. Briesewitz, L. Wang, C. Fernandez-Cymering, S. Volinia, C.-G. Liu, S. Schnittger, T. Haferlach, et al.
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
PNAS, March 11, 2008; 105(10): 3945 - 3950.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients
Blood, March 1, 2008; 111(5): 2527 - 2537.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
B. Lowenberg
Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety
Hematology, January 1, 2008; 2008(1): 1 - 11.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
T. Haferlach
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
Hematology, January 1, 2008; 2008(1): 400 - 411.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, K. Maharry, S. P. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. Mrozek, C. D. Baldus, A. J. Carroll, B. L. Powell, et al.
High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 1, 2007; 25(22): 3337 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Resende, G. Regalo, C. Duraes, F. Carneiro, and J. C. Machado
Genetic Changes of CEBPA in Cancer: Mutations or Polymorphisms?
J. Clin. Oncol., June 10, 2007; 25(17): 2493 - 2494.
[Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, A. Corbacioglu, R. F. Schlenk, H. Dohner, and K. Dohner
In Reply
J. Clin. Oncol., June 10, 2007; 25(17): 2494 - 2495.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Bennett, B. Hackanson, L. T. Smith, C. D. Morrison, J. C. Lang, D. E. Schuller, F. Weber, C. Eng, and C. Plass
Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein {alpha} Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma
Cancer Res., May 15, 2007; 67(10): 4657 - 4664.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Akasaka, T. Balasas, L. J. Russell, K.-j. Sugimoto, A. Majid, R. Walewska, E. L. Karran, D. G. Brown, K. Cain, L. Harder, et al.
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood, April 15, 2007; 109(8): 3451 - 3461.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features
Blood, February 1, 2007; 109(3): 874 - 885.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood, January 15, 2007; 109(2): 431 - 448.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 392 - 397.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. J. Wouters, I. Louwers, P. J. M. Valk, B. Lowenberg, and R. Delwel
A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML
Blood, January 1, 2007; 109(1): 389 - 390.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Marzac, I. Teyssandier, O. Calendini, J.-Y. Perrot, A.-M. Faussat, R. Tang, N. Casadevall, J.-P. Marie, and O. Legrand
Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia
Clin. Cancer Res., December 1, 2006; 12(23): 7018 - 7024.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Heuser, G. Beutel, J. Krauter, K. Dohner, N. von Neuhoff, B. Schlegelberger, and A. Ganser
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
Blood, December 1, 2006; 108(12): 3898 - 3905.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. D. Radmacher, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, J. W. Vardiman, P. Paschka, T. Vukosavljevic, C. D. Baldus, J. E. Kolitz, et al.
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
Blood, September 1, 2006; 108(5): 1677 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Blood, July 1, 2006; 108(1): 63 - 73.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood, May 15, 2006; 107(10): 3847 - 3853.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Thiede, S. Koch, E. Creutzig, C. Steudel, T. Illmer, M. Schaich, G. Ehninger, and for the Deutsche Studieninitiative Leukamie (DSIL)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
Blood, May 15, 2006; 107(10): 4011 - 4020.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Chattopadhyay, E.-Y. Gong, M. Hwang, E. Park, H. J. Lee, C. Y. Hong, H.-S. Choi, J.-H. Cheong, H. B. Kwon, and K. Lee
The CCAAT Enhancer-Binding Protein-{alpha} Negatively Regulates the Transactivation of Androgen Receptor in Prostate Cancer Cells
Mol. Endocrinol., May 1, 2006; 20(5): 984 - 995.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
H. S. Radomska, D. S. Basseres, R. Zheng, P. Zhang, T. Dayaram, Y. Yamamoto, D. W. Sternberg, N. Lokker, N. A. Giese, S. K. Bohlander, et al.
Block of C/EBP{alpha} function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
J. Exp. Med., February 21, 2006; 203(2): 371 - 381.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. Mrozek and C. D. Bloomfield
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia
Hematology, January 1, 2006; 2006(1): 169 - 177.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al.
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., December 20, 2005; 23(36): 9234 - 9242.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Schnittger, C. Schoch, W. Kern, C. Mecucci, C. Tschulik, M. F. Martelli, T. Haferlach, W. Hiddemann, and B. Falini
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Blood, December 1, 2005; 106(12): 3733 - 3739.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Dohner, R. F. Schlenk, M. Habdank, C. Scholl, F. G. Rucker, A. Corbacioglu, L. Bullinger, S. Frohling, H. Dohner, and for the AML Study Group (AMLSG)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Blood, December 1, 2005; 106(12): 3740 - 3746.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Stegmaier, S. M. Corsello, K. N. Ross, J. S. Wong, D. J. DeAngelo, and T. R. Golub
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Blood, October 15, 2005; 106(8): 2841 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
I. Paz-Priel, D. H. Cai, D. Wang, J. Kowalski, A. Blackford, H. Liu, C. A. Heckman, A. F. Gombart, H. P. Koeffler, L. M. Boxer, et al.
CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) and C/EBP{alpha} Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-{kappa}B p50
Mol. Cancer Res., October 1, 2005; 3(10): 585 - 596.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Bullinger and P. J.M. Valk
Gene Expression Profiling in Acute Myeloid Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6296 - 6305.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Tallman, D. G. Gilliland, and J. M. Rowe
Drug therapy for acute myeloid leukemia
Blood, August 15, 2005; 106(4): 1154 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-Y. Shih, C.-F. Huang, T.-L. Lin, J.-H. Wu, P.-N. Wang, P. Dunn, M.-C. Kuo, and T.-C. Tang
Heterogeneous Patterns of CEBP{alpha} Mutation Status in the Progression of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia to Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2005; 11(5): 1821 - 1826.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-I. Lin, C.-Y. Chen, D.-T. Lin, W. Tsay, J.-L. Tang, Y.-C. Yeh, H.-L. Shen, F.-H. Su, M. Yao, S.-Y. Huang, et al.
Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells
Clin. Cancer Res., February 15, 2005; 11(4): 1372 - 1379.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Farag, A. S. Ruppert, K. Mrozek, R. J. Mayer, R. M. Stone, A. J. Carroll, B. L. Powell, J. O. Moore, M. J. Pettenati, P. R.K. Koduru, et al.
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., January 20, 2005; 23(3): 482 - 493.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. S. Tallman
New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents
Hematology, January 1, 2005; 2005(1): 143 - 150.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Frohling and H. Dohner
Disruption of C/EBP{alpha} Function in Acute Myeloid Leukemia
N. Engl. J. Med., December 2, 2004; 351(23): 2370 - 2372.
[Full Text] [PDF]

Home page
 NEJMHome page
M. L. Smith, J. D. Cavenagh, T. A. Lister, and J. Fitzgibbon
Mutation of CEBPA in Familial Acute Myeloid Leukemia
N. Engl. J. Med., December 2, 2004; 351(23): 2403 - 2407.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al.
Gene expression profiling of pediatric acute myelogenous leukemia
Blood, December 1, 2004; 104(12): 3679 - 3687.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Perrotti, G. Marcucci, and M. A. Caligiuri
Loss of C/EBP{alpha} and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
J. Clin. Oncol., February 15, 2004; 22(4): 582 - 584.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online